Advances in Diagnosis and Treatment of Amyloidosis

Dear Colleagues,

In recent years, advances in the diagnosis and treatment of amyloidosis have been abundant and encouraging. The utilization of appropriate techniques to confirm the diagnosis and subtype of amyloid deposition is now increasingly critical as there are effective treatments for both light chain (AL) and transthyretin (TTR) amyloidosis that need to be selected thoughtfully. Immunotherapeutic approaches have led to improved outcomes for patients with newly diagnosed AL amyloidosis, including the first FDA-approved regimen of daratumumab with Cytoxan, bortezomib, and dexamethasone (Dara-CyBorD). Furthermore, immune-based strategies have also contributed to improved outcomes for relapsed disease. The roles of other therapies for AL including high-dose melphalan and autologous stem cell transplantation are evolving. Likewise, for TTR amyloidosis, modern diagnostic modalities and new treatments that either inhibit the production of TTR or stabilize the protein to prevent misfolding are increasingly available. This Special Issue will highlight advances that help shape the approach clinicians take to make an accurate diagnosis of amyloidosis and select the optimal upfront treatment strategy. We also describe advances made for patients with relapsed disease and highlight future modalities under investigation. Finally, the diagnosis and management of specific organ disease including cardiomyopathy, nephropathy, and peripheral/autonomic neuropathy due to amyloidosis will also be discussed.

Dr. Michael Rosenzweig
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• amyloidosis
• transthyretin (TTR)
• autologous stem cell transplantation (ASCT)
• chemotherapy
• immunotherapy
• cardiomyopathy
• nephropathy
• neuropathy